Gustavo A. Rosario Benitez

Array ( [id] => 13733175 [patent_doc_number] => 20180371055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => Novel Epitope for Switching to TH2 Cell and Use Thereof [patent_app_type] => utility [patent_app_number] => 15/866061 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622121 [patent_doc_number] => 20180362612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => NOVEL EPITOPE FOR SWITCHING TO TH1 CELL AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/866042 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206251 [patent_doc_number] => 20190365812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/475803 [patent_app_country] => US [patent_app_date] => 2018-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875561 [patent_doc_number] => 11447562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => RP215 chimeric antigen receptor construct and methods of making and using same [patent_app_type] => utility [patent_app_number] => 16/474934 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 35 [patent_no_of_words] => 7455 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16474934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909001 [patent_doc_number] => 20180194842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/849931 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178241 [patent_doc_number] => 20190359712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/472346 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16472346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603393 [patent_doc_number] => 20180092961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY [patent_app_type] => utility [patent_app_number] => 15/838639 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15838639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145001 [patent_doc_number] => 20190350978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => PRODUCTION OF ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/465140 [patent_app_country] => US [patent_app_date] => 2017-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357339 [patent_doc_number] => 20180230209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => HUMAN ANTIBODY MOLECULES FOR IL-13 [patent_app_type] => utility [patent_app_number] => 15/823296 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15823296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769402 [patent_doc_number] => 11401330 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Glycan-interacting compounds and methods of use [patent_app_type] => utility [patent_app_number] => 16/462075 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 56814 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837472 [patent_doc_number] => 20180170997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => NOVEL EPITOPE FOR SWITCHING TO TH17 CELL AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/815396 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061365 [patent_doc_number] => 10689617 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-06-23 [patent_title] => T-cell receptor-deficient T cell compositions [patent_app_type] => utility [patent_app_number] => 15/815261 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14020 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061363 [patent_doc_number] => 10689616 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-06-23 [patent_title] => T-cell receptor-deficient t cell compositions [patent_app_type] => utility [patent_app_number] => 15/815197 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14007 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086403 [patent_doc_number] => 20190338012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/343252 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715663 [patent_doc_number] => 20190248895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => TREATMENT WITH ANTI-KIR3DL2 AGENTS [patent_app_type] => utility [patent_app_number] => 16/343796 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15574443 [patent_doc_number] => 10577588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GVHD) [patent_app_type] => utility [patent_app_number] => 15/786724 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 27 [patent_no_of_words] => 26171 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15786724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393399 [patent_doc_number] => 11242401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Monoclonal antibody and a method of use for the treatment of lupus [patent_app_type] => utility [patent_app_number] => 16/343127 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 8304 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16893233 [patent_doc_number] => 11034766 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Anti-B7-H6 antibody, fusion proteins, and methods of using the same [patent_app_type] => utility [patent_app_number] => 15/784342 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 15 [patent_no_of_words] => 7040 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641319 [patent_doc_number] => 20180105604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => METHODS FOR REDUCING PROTEINURIA IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY [patent_app_type] => utility [patent_app_number] => 15/782627 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12226675 [patent_doc_number] => 09913902 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Purified antibody composition' [patent_app_type] => utility [patent_app_number] => 15/718621 [patent_app_country] => US [patent_app_date] => 2017-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 64261 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15718621 [rel_patent_id] =>[rel_patent_doc_number] =>)